Biopta Stretches Blood Vessel Viability Using Abcellute Cell Preservation Technology

CARDIFF, Wales--(BUSINESS WIRE)--Early stage studies using human tissue samples are increasingly recognised as key to reducing drug failure rates. Now in a major breakthrough Abcellute’s non-cryogenic cell preservation technology has been successful trialled by Biopta Ltd, a CRO specializing in human tissue in vitro pharmacology. Biopta were able to use Abcellute’s matrix to maintain the viability of fresh blood vessels over 5 days for use on their cardiovascular in vitro testing systems including Biopta’s first instrument, the PM-1, which provides real-time information on the vascular effects of drugs in living tissues.